Navigation Links
Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Date:2/15/2008

NEW HAVEN, Conn., Feb. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that the Company had paid interest due February 15, 2008 on its 7.75% Convertible Senior Notes due 2012 (the "Notes"). The aggregate principal amount of the Notes is $60 million.

The Company paid $2,376,666.67 through the issuance of shares of its registered Common Stock. Approximately $2,376,345.60 was paid in 5,500,800 shares of Common Stock, based on today's closing bid price of $0.432, which is approximately equal to 91.68 shares of Common Stock per each $1,000 principal amount of Notes. Cash interest was paid in lieu of fractional shares.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a pivotal Phase II trial as a single agent in elderly patients with de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk f
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals Announces Additions to Management Team
2. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
3. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
4. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast
5. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
6. Vion Pharmaceuticals Holds Special Meeting of Stockholders
7. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
8. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
11. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Columbia, Md. (PRWEB) August 19, 2014 ... integrated liquid chromatography systems, Prominence-i and Nexera-i, adding ... UHPLC systems. Combining excellent functionality, an intuitive operating ... performance and a more efficient workflow for conventional ... systems feature innovative, intuitive and intelligent design so ...
(Date:8/19/2014)... IRVINE, Calif. (PRWEB) August 19, 2014 ... Indiegogo campaign to raise $200,000 to fund a ... diagnostic device. , This development is a ... one-size-fits-all model of care to the implementation of ... patient-centric method of practicing medicine. , Indiegogo contributions ...
(Date:8/19/2014)... XenoTech announces an exclusive partnership with ... from bioactive small molecules. Based on an ... convenient and timely assessment of critical metabolite and ... of Commercial Operations, Christian Darabant, “the value of ... be measured directly by comparison with the approximate ...
(Date:8/19/2014)... In November 2012, the European Union (EU) ... (PBRER) in a new PSUR – responding to the increasing ... of a drug. Adopted in many regions, the main objectives ... a comprehensive and critical analysis of new or emerging information ... any new evidence of the potential benefits of a drug; ...
Breaking Biology Technology:Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer ... its Board of Directors.  Mr. Voyticky is currently President ... an oil and gas exploration company, and has more ... merger and acquisition consulting. The Genesis Biopharma Board now ...
... WOODLANDS, Texas, July 18, 2011 One of the ... to achieve Meaningful Use requirements in the coming years. ... learning more about Meaningful Use requirements and how these ... a free webinar at 1 p.m. EDT (10 a.m. ...
... 90% , Reduction in HIV ... SEEK, a privately owned biopharmaceutical company specializing,in ... of its HIV-v vaccine which demonstrates a one,log (approx ... placebo group, after just a single vaccine,injection. Gregory Stoloff, ...
Cached Biology Technology:Genesis Biopharma Names David Voyticky to Board of Directors 2Medicare HIT Incentive Update for the Oncology Practice - Free Educational Webinar 2Medicare HIT Incentive Update for the Oncology Practice - Free Educational Webinar 3SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 2SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 3SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 4SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 5SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 6
(Date:8/19/2014)... , August 19, 2014 Smart ... Digital Wallet Choices as latest developments, ad campaigns and ... (NASDAQ: EBAY ), Amazon.com Inc. (NASDAQ: ... ), Google Inc. (NASDAQ: GOOG ) and ... NXTD) a biometric authentication company focused on the growing ...
(Date:8/19/2014)... protect their young have bigger brains than counterparts that ... British Columbia study. , Stickleback fish are well known ... male of the species, rather than the female, cares ... females and researchers wanted to find out if the ... caregivers. , In the study, published recently in ...
(Date:8/18/2014)... major Arizona watershed may lose access to important segments ... is reduced by the effects of climate warming, new ... in the Verde River Basin, are already threatened or ... resources throughout the river and its tributary streams. The ... (Gila robusta) and Sonora sucker (Catostomus insignis). , A ...
Breaking Biology News(10 mins):Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 2Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 3Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 4Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 5Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 6Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 7Climate change will threaten fish by drying out Southwest US streams, study predicts 2Climate change will threaten fish by drying out Southwest US streams, study predicts 3
... at Johns Hopkins have discovered how to block a molecular ... oxygen during a stroke. The Hopkins study, conducted on mice, ... protein on the surface of nerve cells called the EP1 ... as ONO-8713, turns it off. , The finding ...
... garden compost to forest greenery, the mold Aspergillus fumigatus ... its impact. The most common mold causing infection, A. ... among people with weakened immune systems. , Now, in ... scientists at The Institute for Genomic Research (TIGR) and their ...
... Chinese men are selectively switching from traditional Chinese ... but sticking with tradition for ailments such as ... published in Environmental Conservation. , The finding supports ... at the advent of Viagra's commercial release in ...
Cached Biology News:Blocking the nerve receptor EP1 in mouse models reduces brain damage caused by stroke 2Blocking the nerve receptor EP1 in mouse models reduces brain damage caused by stroke 3Breaking the mold: Research teams sequence three fungus genomes 2Viagra's hidden help for wildlife 2
... Features hardwall acrylic panels mounted ... to form a free-standing modular ... Class 10/ISO 3. Optional ceiling ... ionizers are configured to customer ...
...
... This modular benchtop fume hood ... allowing safe indoor release of ... most organic contaminants. Configurations are ... flow; options include final HEPA ...
...
Biology Products: